title: Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
abstract: Parkinson's disease (PD) is characterized by progressive loss of dopamine (DA) neurons in the nigrostriatal system and by the presence of Lewy bodies (LB), proteinaceous inclusions mainly composed of filamentous α-synuclein (α-Syn) aggregates. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was adopted to generate PD models in C57BL/6 mice. In the present study, we investigated the effect of geraniol (GE) against α-Syn aggregation on MPTP induced mouse model of PD in dose dependant manner. When pretreatment of GE improved neuromuscular impairment, TH expressions and decreases α-Syn expressions in MPTP intoxicated PD mice by dose dependent manner. In addition, we confirmed that sub-chronic administration of MPTP in mice leads to permanent neuromuscular deficits and depletion of dopamine and its metabolites. Our results suggest that GE is beneficial for the treatment of PD associated with neuromuscular disability and LB aggregation.
authors.affiliation: Division of Biochemistry, Faculty of Medicine, Raja Muthaiah Medical College, Annamalai University, Annamalainagar 608 002, Tamilnadu, India.
authors.forename: Karamkolly R
authors.initials: KR
authors.lastname: Rekha
authors.forename: Govindasamy P
authors.initials: GP
authors.lastname: Selvakumar
authors.forename: Karunanithi
authors.initials: K
authors.lastname: Santha
authors.forename: Ramu
authors.initials: R
authors.lastname: Inmozhi Sivakamasundari
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000080462:Acyclic Monoterpenes; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000378:metabolism; D016631:Lewy Bodies / Q000187:drug effects / Q000378:metabolism; D020267:MPTP Poisoning / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008995:Monoamine Oxidase / Q000378:metabolism; D009468:Neuromuscular Diseases / Q000139:chemically induced / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000188:drug therapy* / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism; D013729:Terpenes / Q000008:administration & dosage*; D051844:alpha-Synuclein / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000080462:Acyclic Monoterpenes; D013729:Terpenes; D051844:alpha-Synuclein; D015102:3,4-Dihydroxyphenylacetic Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase; C007836:geraniol; D004298:Dopamine
keywords: Degeneration; Geraniol; MPTP; Neuroprotective; Parkinson’s disease